DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for joint disease — screening already-approved drugs against its 34-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleJoint disease maps to a 34-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for joint disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
leucine carboxyl methyltransferase 1 (LCMT1) — LCMT1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet sahdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3IEI · 1.9 Å · ligand S-ADENOSYL-L-HOMOCYSTEINE (SAH). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Indian Journal of Rheumatology · 2012 · 0 citations · open access
Arthralgia and limb pains: Pseudo-rheumatoid genetic disorders
AbstractAbstract Limb and joint pains can be the manifestation of many infectious, autoimmune or genetic disorders of the bones and joints. In addition, it may also be the manifestation of many genetic or non-genetic disorders of other systems. The monogenic disorders manifesting with joint and limb pains need to be suspected when the rheumatologist concludes that the disorder does not fit the pattern of a specific rheumatic disease. The accurate diagnosis is important as specific treatments are available for some genetic disorders. Diagnosis of genetic disorders also has implications for the family and indicates the need for genetic counselling. In this article, the various situations where a genetic cause for limb and joint pains need to be suspected are discussed. In addition, there is a brief review of some monogenic disorders which often present to the rheumatologist as joint disease.
Nonsteroidal Therapy in Inflammatory Joint Disease
AbstractEfforts to develop alternatives to salicylates for the treatment of inflammatory joint diseases have thus far, with the exception of gout, met with only modest success. While these efforts continue, the guidelines presented here suggest how salicylates and other available agents can be employed more effectively to stabilize and maintain the great majority of patients, reserving long-term systemic steroids for only about 5%.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
